Pfizer Inc. (NYSE:PFE) Shares Bought by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 110.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 227,323 shares of the biopharmaceutical company’s stock after purchasing an additional 119,111 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Pfizer were worth $6,031,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the 4th quarter valued at about $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer in the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the fourth quarter worth approximately $28,000. Noble Wealth Management PBC purchased a new position in Pfizer during the fourth quarter worth approximately $31,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $22.95 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $130.16 billion, a price-to-earnings ratio of 16.28, a PEG ratio of 0.64 and a beta of 0.67. The business’s 50 day moving average is $24.58 and its two-hundred day moving average is $25.97.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 earnings per share. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.49%. Pfizer’s payout ratio is 121.99%.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PFE shares. UBS Group cut their target price on Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 8th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday. They issued a “neutral” rating and a $24.00 price objective for the company. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $29.57.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.